BioSpace News Archive

The Foundation for the National Institutes of Health announces two new additions to the FNIH Board of Directors, Nina Kjellson, General Partner at Canaan, and Charles Reinhart III, Chief Financial Officer at Pacira BioSciences, Inc.

Accelus announced that it has received a significant financial investment through a $20 million debt facility from Symbiotic Capital.

Inflammasome Therapeutics (https://www.inflam.com), a clinical-stage, private company developing a new class of inflammasome inhibitor drugs, Kamuvudines, as therapies for prevalent, degenerative diseases, announced the first patient has been dosed in a Phase 1 study of one of the company’s novel compounds in the treatment of diabetic macular edema (DME).

GE HealthCare, a leader in precision care innovation, will announce its fourth quarter and full year 2023 financial results before the market opens on Tuesday, February 6, 2024.

CNS Pharmaceuticals, Inc. announced it has appointed Amy Mahery to its Board of Directors, effective upon completion of a financing.

Vivtex Corporation (“Vivtex”) and AI Proteins, Inc., a growing biotechnology company that utilizes computational de novo protein design to create novel therapeutic miniproteins, today announced they have entered a strategic R&D collaboration to develop novel, oral biologic therapies for inflammatory diseases.

Savaria Corporation (“Savaria”) (TSX: SIS) a global leader in the accessibility industry, announces its first-ever Investor Day to be held in the Greater Toronto Area on April 9, 2024.

Sharps Technology, Inc. and Roncadelle Operationssigned a Letter of Intent to enter into a sales and marketing agreement which would enable the Company and Roncadelle to cooperatively sell and distribute each other’s products to their respective areas of influence and expand Sharps’ American-based product market into Europe, the Middle East, Africa, and the Asia-Pacific region.

Immunitas Therapeutics today announced the appointment of Annalisa D’Andrea, Ph.D., as Chief Scientific Officer (CSO).

BPGbio Presents Updated Phase 2a Clinical Results Demonstrating Benefit of BPM31510 in Combination with Chemotherapy in Pancreatic Cancer at ASCO GI being held January 18-20, 2024, in San Francisco, Calif.